Introduction Ipsen SA (Ipsen) is a French biopharmaceutical company headquartered in Paris, France, with a focus on transformative medicines in three therapeutic areas: oncology, rare disease and neuroscience.Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in more than 100 countries with direct commercial presence in over 30 countries.
Ipsen)is a global specialty biopharmaceutical company engaged in the manufacturing and distribution of drugs for the treatment of cancer, rare diseases, and neurological diseases, including specialty pharmaceutical products. The company develops and commercializes novel medicines for cancer, neuroscience and rare diseases and offers products to treat gastrointestinal disorders, and neurodegenerative pathologies. Ipsen sells its drugs through a network of distributors and directly to hospitals in a few countries. The company operates its research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, and rest of the world. Ipsen is headquartered in Paris, France. |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 43 |
Toxin | 5 |
Synthetic peptide | 3 |
Biological products | 2 |
TCR-T Cell therapy | 2 |
Target |
Mechanism PPARα agonists [+1] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date10 Jun 2024 |
Target |
Mechanism RARγ agonists |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Canada |
First Approval Date21 Jan 2022 |
Target |
Mechanism ISBT inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. European Union [+3] |
First Approval Date16 Jul 2021 |
Start Date02 Sep 2025 |
Sponsor / Collaborator ![]() [+1] |
Start Date30 Jun 2025 |
Sponsor / Collaborator |
Start Date30 Jun 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Lanreotide Acetate ( SSTR ) | Acromegaly More | Approved |
AbobotulinumtoxinA (Ipsen Biopharm Ltd) ( SNAP25 ) | Dystonia More | Approved |
Cabozantinib (s)-Malate ( AXL x RET x ROS1 x TYRO3 x Tie-2 x TrkB x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit x c-Met ) | Differentiated Thyroid Gland Carcinoma More | Approved |
Palovarotene ( RARγ ) | Myositis Ossificans More | Approved |
Elafibranor ( PPARα x PPARδ ) | Primary Biliary Cholangitis More | Approved |